AtriCure, Inc. — Form 8-K
Filed July 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
AtriCure reported Q2 2026 worldwide revenue of $153.6 million (up 12.8% YoY), with net income of $9.0 million and adjusted EBITDA of $27.3 million, compared to a $6.2 million operating loss in Q2 2025. U.S. revenue grew $15.0 million (13.6%) to $125.6 million, driven by cryoSPHERE MAX pain management and appendage management devices; gross margin expanded 269 basis points to 77.2%. Full-year 2026 guidance: $602–610 million revenue, $85–89 million adjusted EBITDA, $0.24–0.32 adjusted EPS.
Why this rating
Solid growth and profitability turnaround (operating loss to profit) matter operationally, but represent ordinary execution at ~10% scale of $1.6B market cap—no M&A, guidance unchanged materially, no major structural change.
See more from July 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.